CN1197673A - Chinese medicine 'Xiaoyangtang' for curing acute and chronic hepatitis B - Google Patents
Chinese medicine 'Xiaoyangtang' for curing acute and chronic hepatitis B Download PDFInfo
- Publication number
- CN1197673A CN1197673A CN 98113876 CN98113876A CN1197673A CN 1197673 A CN1197673 A CN 1197673A CN 98113876 CN98113876 CN 98113876 CN 98113876 A CN98113876 A CN 98113876A CN 1197673 A CN1197673 A CN 1197673A
- Authority
- CN
- China
- Prior art keywords
- radix
- xiaoyangtang
- examples
- hepatitis
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Xiaoyangtang decoction as a kind of Chinese medicine consists of mainly Astragalus membranaceus, Chinese angelica, Radix Puerariae, red sage, Codonopsis Pilosulae, and the other seven Chinese medicinal materials. The present invention aims at providing medicine for curing acute and chronic hepatitis B with low cost, convenience in application, less side effect and other merits.
Description
The present invention relates to a kind of Chinese medicine preparation for the treatment of hepatitis B.
Hepatitis B is a kind of infectious disease of current serious harm humans health, has characteristics such as strong, popular wide, the sickness rate height of infectiousness.At present, it is hepatitis B surface antigen carriers that there are 1.2 hundred million populations in China, and they are main sources of infection of hepatitis B, have become China's serious social concern.For a long time, scholar both domestic and external is devoted to the study on prevention of hepatitis B infection always, but hepatitis B viruses (HBV) does not have the specially good effect way in the body to removing.Both at home and abroad several anti-HBV medicine and the therapy of generally acknowledging costs an arm and a leg, and negative interaction is big, weak curative effect, because of the course of treatment long, quiet of need use inconvenience.As " interferon " treatment chronic viral hepatitis B, be 18-37% at hbv replication mark negative conversion rate, 3-6 month is a course of treatment, intramuscular injection, ten thousand yuan of required medical care expenses 3-6, and negative interactions such as cold syndrome, leukopenia are arranged." Ah former times's network Wei " effective percentage is 37.3%, and per two months is a course of treatment, needs quiet, and 5,000 yuan of required expensess for medicine have negative interactions such as fever, erythra, leukopenia.Treating the hepatitis B effective percentage from the four defeated ruling by law of body LAK cell 44%, 2 month was a course of treatment, needs intramuscular injection, and contraindication is arranged.Above medicine need cooperate other the liver protecting and ALT lowering medicine that hepatitis is cured.In treatment, can not treating both the principal and secondary aspects of a disease, though some hepatitis B patient can obtain " false ", the misfortune that be unable to escape recurrence eventually, cancerates.Some Chinese medicine Time of Administration is long, and the need that have were taken more than 1 year.Simultaneously also exist the medicine source few, problem such as cost an arm and a leg.
At problem set forth above, the invention provides a kind of Chinese medicine product Xiaoyangtang, its purpose is to solve the drug price costliness of treatment acute and chronic hepatitis B, the medication inconvenience, negative interaction is big, can not treating both the principal and secondary aspects of a disease, the course of treatment long existing problem.
The present invention is achieved through the following technical solutions:
The Xiaoyangtang of treatment acute and chronic hepatitis B, it mainly is made up of following component: (with weight ratio)
Radix Astragali 30-40, Radix Angelicae Sinensis 10-20, Radix Puerariae 25-35, Radix Salviae Miltiorrhizae 25-35, Radix Codonopsis 20, Poria 15-20, Polyporus 20-25, Fructus Ligustri Lucidi 20, Radix Isatidis 20-40, Folium Isatidis 15-25, Herba Taraxaci 20-30, Herba Artemisiae Scopariae 15-30.
This Xiaoyangtang also includes following component except that above component: (with weight ratio)
Ganoderma 3-5, Radix Sophorae Tonkinensis 20-25, Radix Scutellariae 20-30, Radix Platycodonis 20-30, Semen Raphani 30, Fructus Crataegi 20-30, Flos Lonicerae 15-20, Fructus Forsythiae 15-20, Radix Sophorae Flavescentis 50, Flos Carthami 15, Radix Paeoniae Rubra 80-100.
Advantage of the present invention and effect:
The method that the present invention treats acute and chronic hepatitis B is simple, and oral getting final product need not quiet, outpatient service and all can treating in hospital.Expense is low, and per two months is a course of treatment, 500 yuan of required expenses.The medicine source is extensive, and treating both the principal and secondary aspects of a disease, does not have any negative interaction at good effect, has antiviral, adjusts body's immunity, falls enzyme, and jaundice eliminating improves liver function, prevents hepatic fibrosis and prevents effect such as canceration.Adopt this law treatment all to receive promising result to hepatitis gravis, its clinical cure rate 100%, none example is dead.In clinical symptom disappearance, HBsAg, HBeAg and anti--HBCIgG are turned out cloudy, HBeAg negative conversion rate acute hepatitis is 100%, chronic hepatitis is 62.5%, apparently higher than the best antiviral agents-interferon of generally acknowledging both at home and abroad at present, required expense is lacked ten thousand yuans of 2-4 than interferon, saves the thousands of units of medical expense than the most cheap ZHULINGDUOTANG ZHUSHEYE.Patient can not be in hospital, and patient's sufferings are promptly removed in the treatment of edge work limit, can reduce the financial burden again, have saved large quantities of medical care expensess to country simultaneously, meet very much the national conditions that China has quite modest financial resources, national income is not high, so very high social benefit and economic benefit are arranged.
Below in conjunction with embodiment, clinical experiment the present invention is specifically described:
1, following Chinese herbal medicine is prepared: (with weight ratio)
The Radix Astragali 35, Radix Angelicae Sinensis 20, Radix Puerariae 25, Radix Salviae Miltiorrhizae 30, Radix Codonopsis 20, Poria 20, Polyporus 20, Fructus Ligustri Lucidi 20, Radix Isatidis 40, Folium Isatidis 15, Herba Taraxaci 30, Herba Artemisiae Scopariae 30.
With above-mentioned prescription add water, stir, decoct, common process process such as overanxious, bottling, 200 milliliters of every pair of decoctings, day clothes get final product for twice.
2, following Chinese herbal medicine is prepared: (with weight ratio)
The Radix Astragali 40, Radix Angelicae Sinensis 10, Radix Puerariae 30, Radix Salviae Miltiorrhizae 30, Radix Codonopsis 20, Poria 15, Polyporus 25, Fructus Ligustri Lucidi 20, Radix Isatidis 30, Folium Isatidis 15, Herba Taraxaci 25, Herba Artemisiae Scopariae 30.
Ganoderma 3, Radix Sophorae Tonkinensis 20, Radix Scutellariae 20, Radix Platycodonis 20, Semen Raphani 30, Fructus Crataegi 20, Flos Lonicerae 15, Fructus Forsythiae 15, Radix Sophorae Flavescentis 50, Flos Carthami 15, Radix Paeoniae Rubra 80.
With above-mentioned prescription add water, stir, decoct, common process process such as overanxious, bottling, 200 milliliters of every pair of decoctings, day clothes get final product for twice.
3, following Chinese herbal medicine is prepared: (with weight ratio)
The Radix Astragali 30, Radix Angelicae Sinensis 15, Radix Puerariae 35, Radix Salviae Miltiorrhizae 25, Radix Codonopsis 20, Poria 17, Polyporus 23, Fructus Ligustri Lucidi 20, Radix Isatidis 35, Folium Isatidis 15, Herba Taraxaci 20, Herba Artemisiae Scopariae 15, Ganoderma, Radix Sophorae Tonkinensis, Radix Scutellariae, Radix Platycodonis, Semen Raphani, Fructus Crataegi, Flos Lonicerae, Fructus Forsythiae.
Ganoderma 5, Radix Sophorae Tonkinensis 25, Radix Scutellariae 30, Radix Platycodonis 30, Semen Raphani 30, Fructus Crataegi 30, Flos Lonicerae 20, Fructus Forsythiae 20, Radix Sophorae Flavescentis 50, Flos Carthami 15, Radix Paeoniae Rubra 90.
With above-mentioned prescription add water, stir, decoct, common process process such as overanxious, bottling, 200 milliliters of every pair of decoctings, day clothes get final product for twice.
Under the prerequisite that does not affect the treatment, can change dosage form, as: cream ball and electuary etc., more convenient patient takes.
Clinical and experimental study;
(1) case is selected: hepatitis B patient 30 examples, acute hepatitis 10 examples wherein, chronic hepatitis 20 examples; Man's 27 examples, women 3 examples; Minimum 15 years old, maximum 72 years old, 15-20 year 8 examples, 31-50 year 19 examples; 51-72 year 3 examples; HBSAg.HBeAg and anti--HBCIgG positive person 23 examples, HBSAg resists-HBe and anti--HBCIgG positive person 5 examples, anti--HBCIgG positive person 1 example, only HBV-DNA positive person 1 example.Severe jaundice 12 examples, moderate jaundice 4 examples, hepatitis gravis 4 examples.
Get matched group at random: 30 examples, acute hepatitis 9 examples, chronic hepatitis 21 examples; Man's 26 examples, women 4 examples; Minimum 12 years old, maximum 58 years old, 12-30 year 4 examples, 31-50 year 18 examples, HBSAg and anti--HBCIgG positive person 18 examples, HBSAg, anti--HBe and anti--HBCIgG positive person 10 examples, HBeAg and resisting-the HBCIgG1 example resists-HBCIgG positive person 1 example.
(2) experimental technique: treatment group Xiaoyangtang is decocted in water for oral dose with disease plus-minus potion every day, serve on two months, outpatient service or all suitable in hospital, and inpatient adds a glucose, vitamin C, potassium chloride.
Matched group at random: be in hospital quiet glucose, compound Salviae Miltiorrhizae, vitamin C, potassium chloride, potenlin, oral bifendate.Liver function and transaminase often cure again and leave hospital, and continue by taking bifendate the course of treatment back of leaving hospital.Each organizes the equal 10-15 of the case days full items of chemical examination liver function once, HBV-M of check in 15-20 days.
Experimental result
(1) criterion: 1, hepatitis symptom disappears, and transaminase and total bilirubin are normal again, are clinical cure.
2, the double above feminine gender of HBV-M is cloudy the commentaries on classics.
(2) lab testing:
1, two groups of HBV-M are cloudy changes and negative conversion rate sees Table 1, table 2
Table 1 liang group acute hepatitis b HBV-M negative conversion rate contrast
Matched group HBV-M p value is at random organized in treatment
The example number, the cloudy revolution 100%HBSAg of cloudy revolution 100% routine number 86 75.0 74 57.1>0.05HBeAg 77 100 76 85.7>0.05 anti--HBE 11 100 100---anti--HBCIgG 85 62.5 92 22.0>0.05
Table 2 liang group chronic viral hepatitis B HBV-M negative conversion rate contrast
Matched group HBV-M p value is at random organized in treatment
The example number, the cloudy revolution 100%HBSAg of cloudy revolution 100% routine number 20 1 5.0 21 00>0.05HBeAg 16 9 62.5 12 2 16.7<0.05 anti--HBE 44 100.0 900<0.05 anti--HBCIgG 20 1 5.0 21 00>0.05
2, this experimental therapy group 30 examples, severe jaundice 12 examples, moderate jaundice 4 examples, GPT>13 examples, hepatitis gravis 4 examples are clinical cure all, cure rate 100%, none example is dead.Matched group 30 examples at random, severe jaundice 5 examples, moderate jaundice 5 examples, clinical cure 25 examples, dead 4 examples, mortality rate 13.3%, in sum, treatment group hepatitis cure rate and HBVM negative conversion rate are all apparently higher than matched group at random.
(3) experimental analysis:
In recent years the viral hepatitis study of pathogenesis is shown, though HBV can duplicate in hepatocyte, and cause cytopathy, but the tissue injury of hepatitis B, not the result of hbv replication, but the immunoreation by body causes, so the inflammation damnification of treatment Type B viral hepatitis, essential method is thoroughly to remove HBV.Do you how remove HBV? the one, suppress virus replication, the 2nd, regulate host immune function, promote self to remove the not cell of infection of infection cell and protection, the cell that has infected is melted, remove HBV and reach.Theoretical basis of the present invention is according to the motherland's medical science and the modern Chinese medicine mechanism of action, in conjunction with modern medicine index and clinical experience for many years, and, intend Xiaoyangtang certainly.Radix Isatidis, Folium Isatidis, Herba Taraxaci have antiviral, improvement or recover liver function, promotion bile secretion in the prescription, reduce the effect of serum bilirubin and serum transaminase, Radix Angelicae Sinensis, Radix Salviae Miltiorrhizae, Radix Codonopsis promote the hepatic protein metabolism, correct white, globulin ratio inversion, and prevent hepatic edema, strengthen the liver detoxification effect.Radix Salviae Miltiorrhizae, Radix Angelicae Sinensis have the hypertrophy that suppresses the liver fiber and promote newborn fiber absorbs in the liver, and this is for preventing that chronic hepatitis from developing into hepatic fibrosis new treatment approach is provided; Poria has antitumor, Polyporus that anticancer effect is arranged; The Radix Astragali, Radix Codonopsis, Fructus Ligustri Lucidi, Polyporus, Radix Angelicae Sinensis have adjustment organism immune response, the particularly Radix Astragali to have two accent effects, promptly adjust cellular immunization, adjust humoral immunization again, and wherein the Radix Astragali and Radix Codonopsis act on better, if can share with Ganoderma, and its effect more.
Claims (2)
1, a kind of Xiaoyangtang for the treatment of acute and chronic hepatitis B, it mainly is made up of following component: (with weight ratio)
Radix Astragali 30-40, Radix Angelicae Sinensis 10-20, Radix Puerariae 25-35, Radix Salviae Miltiorrhizae 25-35, Radix Codonopsis 20, Poria 15-20, Polyporus 20-25, Fructus Ligustri Lucidi 20, Radix Isatidis 20-40, Folium Isatidis 15-25, Herba Taraxaci 20-30, Herba Artemisiae Scopariae 15-30.
2, according to claim 1 fast Xiaoyangtang, it is characterized in that: this Xiaoyangtang also includes following component except that above component: (with weight ratio)
Ganoderma 3-5, Radix Sophorae Tonkinensis 20-25, Radix Scutellariae 20-30, Radix Platycodonis 20-30, Semen Raphani 30, Fructus Crataegi 20-30, Flos Lonicerae 15-20, Fructus Forsythiae 15-20, Radix Sophorae Flavescentis 50, Flos Carthami 15, Radix Paeoniae Rubra 80-100.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN98113876A CN1054075C (en) | 1998-04-01 | 1998-04-01 | Chinese medicine 'Xiaoyangtang' for curing acute and chronic hepatitis B |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN98113876A CN1054075C (en) | 1998-04-01 | 1998-04-01 | Chinese medicine 'Xiaoyangtang' for curing acute and chronic hepatitis B |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1197673A true CN1197673A (en) | 1998-11-04 |
CN1054075C CN1054075C (en) | 2000-07-05 |
Family
ID=5223571
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN98113876A Expired - Fee Related CN1054075C (en) | 1998-04-01 | 1998-04-01 | Chinese medicine 'Xiaoyangtang' for curing acute and chronic hepatitis B |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1054075C (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1095379C (en) * | 1999-10-22 | 2002-12-04 | 黄海平 | Chinese medicine for detoxicating wound and its preparing process |
CN103720918A (en) * | 2014-01-09 | 2014-04-16 | 冯萍 | Traditional Chinese medicine composition for treating jaundice |
CN108498739A (en) * | 2018-06-26 | 2018-09-07 | 桐城市泰安中药材种植专业合作社 | A kind of Chinese medicine and preparation method thereof for treating chronic hepatitis |
-
1998
- 1998-04-01 CN CN98113876A patent/CN1054075C/en not_active Expired - Fee Related
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1095379C (en) * | 1999-10-22 | 2002-12-04 | 黄海平 | Chinese medicine for detoxicating wound and its preparing process |
CN103720918A (en) * | 2014-01-09 | 2014-04-16 | 冯萍 | Traditional Chinese medicine composition for treating jaundice |
CN103720918B (en) * | 2014-01-09 | 2016-04-20 | 冯萍 | A kind of Chinese medicine composition for the treatment of jaundice |
CN108498739A (en) * | 2018-06-26 | 2018-09-07 | 桐城市泰安中药材种植专业合作社 | A kind of Chinese medicine and preparation method thereof for treating chronic hepatitis |
Also Published As
Publication number | Publication date |
---|---|
CN1054075C (en) | 2000-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1065750C (en) | Medicine taken after being mixed with boiling water for liver trouble | |
CN101152539A (en) | Traditional Chinese medicine for treating acute icteric hepatitis | |
CN1644213A (en) | Chinese medicinal preparation for treating liver cancer, hepatitis B cirrhosis and preventing liver fibrillation and preparation thereof | |
CN101342338B (en) | Medicament for treating hepatopathy | |
CN1054075C (en) | Chinese medicine 'Xiaoyangtang' for curing acute and chronic hepatitis B | |
CN1066628C (en) | Medicine for chronic hepatitis B and its preparation | |
CN1063954C (en) | Chinese patent medicine-powder preparation for curing hepatitis B | |
CN1102104A (en) | Adhesive plaster capable of detoxicating and resolving a mass | |
CN1112194C (en) | Compound yexiazhu medicine and preparing process thereof | |
CN101199749A (en) | Chinese medicine for treating AIDS | |
CN1059104C (en) | Capsule for anti hepatitis B | |
CN1923269A (en) | Medicine for treating hepatitis B | |
CN1190229C (en) | Medicine for curing hepatitis B | |
CN1128634C (en) | Hepatitis B recuperating medicine granule | |
CN1176683C (en) | Medicine for treating hepatitis B and other hepatosis | |
CN1047944C (en) | Capsule for curing hepatitis | |
CN1269210A (en) | Intraveous injecta for treating viral hepatitis B and its preparation | |
CN101229291B (en) | Chinese traditional medicine composition for treating virus hepatitis by immunoregulation | |
CN1279074A (en) | Chinese-medicinal pill 'Ganxuetong' | |
CN1086949C (en) | Chinese medicine for hepatitis B and its preparation | |
CN1062167C (en) | Hepatitis curing medicine | |
CN101607071B (en) | Medicine for treating chronic hepatitis B and preparation method thereof | |
CN103520148A (en) | Preparation for auxiliary protection against chemical liver injury | |
CN103536614A (en) | Composition containing soybean phospholipid | |
CN1058404C (en) | Hepatitis B treating medicament |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |